An interventional study of Art Prescription in Mental Health Issue, Anxiety Disorders and Affective Disorders, sponsored by KAVADIA ELENI. Completed at 1 site in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by KAVADIA ELENI · Not applicable, Interventional, and Other
This is a parallel-group randomised-controlled trial aiming to assess the effect of exposure to the arts on mental health and wellbeing of community dwelling recipients of mental health care. The trial constitutes a comparison of two arms: An Art Intervention arm, hereby the Active Group (AG), versus a waitlist control arm (WL).
Design:
This is a randomised controlled trial with two arms: art intervention (any of the arts interventions, see below), which is hereby called Active Group (AG) vs waitlist control (WL). This is a new RCT that is based on a previous RCT performed in 2024 (NCT06361667). This trial has been approved by the Institutional Ethics Committee (Institutional Review Board; Epitropi Vioithikis kai Deontologias) of the UMHRI in Greece (UMHRI session 7/15-10-2024).
This trial will be conducted as part of the novel Arts on Prescription initiative of the Hellenic Ministry of Culture in Greece and at several Ministry-of-Culture-approved Organisations from the field of arts and culture. The University Mental Health, Neurosciences and Precision Medicine Research Institute 'COSTAS STEFANIS' (UMHRI) was commissioned by the Ministry of Culture to organize and conduct the RCT. In the beginning, an open invitation to institutions of culture and mental health has been sent. Cultural organizations presented their action plans for interventional courses.
After quality control by the UMHRI and the Ministry of Culture. the following cultural organizations provided approved action plans: National Gallery - Alexandros Soutsos Museum, National Museum of Contemporary Art Athens, Athens Concert Hall Organization, Greek National Opera, Athens Conservatoire, Michael Cacoyannis Foundation, Stavros Niarchos Foundation Cultural Center (SNFCC), Nikolaos and Dolly Goulandris Foundation - Museum of Cycladic Art, Galilee Palliative Care Centre of the Holy Metropolis of Mesogaia and Lavreotiki, Archaeological Museum of Thessaloniki, Thessaloniki Concert Hall Organization, Metropolitan Organisation of Museums of Visual Arts of Thessaloniki (MOMus)", Kazantzakis Museum, Paul and Alexandra Canellopoulos Museum, National School of Dance (KSOT), Municipal Regional Theatre of Ioannina, National Theatre of Northern Greece, Drama International Short Film Festival (DISFF) Cultural Organization, and Heraklion Archaeological Museum.
AG consists of art intervention sessions that have been a priori developed by each cultural organization, specific to the field of each cultural organization (i.e., theatre, dance, visual arts, music, cinema). The intervention sessions have been elaborated and enhanced based on the previous experience of the NCT06361667 trial; specifically, the differences versus the NCT06361667 trial are the following: i. all Cultural Organizations are offering weekly sessions and there is no variability in the total number of sessions provided, ii. a larger sample is included in this trial to improve the precision of estimates and be able to detect smaller effect sizes (given the potential scalability and public health relevance of the intervention, and iii. this trial includes Cultural Organizations and therefore patients beyond the metropolitan areas of Athens and Thessaloniki.
Participants will be randomly allocated to AG or WL for 12 weeks; that marks the end of the trial period. After completion of the 12-week trial, people who were included in the WL will have the opportunity to receive art on prescription by the Cultural Organizations the participated in the trial, should they wish to take this up.
Randomisation will be performed separately in each Cultural Organization and will be carried out using a computer-generated list provided centrally by SIBA Soft (Athens, Greece), an independent software and project management company.
Frequency of Measurement:
Data will be collected at baseline, including gender, age, educational level, marital status, socioeconomic characteristics, and mental health conditions. The primary and the secondary outcomes will be measured at time points:
Interventional Model Description:
The duration of the RCT will be 12 weeks. The AG group will engage in different art forms (theatre, dance, visual arts, music, and cinema), whereas the WL group will remain in the waiting list.
The AG intervention will consist of sessions and/or performances in one of the five art forms: theatre, dance, visual arts, music and cinema. The number of sessions/performances will be 12 for all art forms over the duration of the trial, based on the specific features of each Cultural Organization.
The intervention activities in the AG group have been organized by each site and approved by the UMHRI and the Hellenic Ministry of Culture creating a space for 8-16 participants per activity.
The intervention consists of weekly visits over three months, featuring a guided tour followed by an art activity. All activities will include a discussion group, fostering reflection and connection, and each session will last approximately 1.5 to 2 hours. UMHRI and Ministry of Culture-approved, experienced professionals from the fields of mental health and arts, will lead the intervention sessions ensuring the safety and support of participants.
Statistical analysis model and sample size calculation The standard practice for RCTs will be followed and a linear mixed effects model will be applied, with random intercepts to estimate the effects of treatment, time, with interaction terms for treatment (AG treatment) and time (6 and 12 weeks). The inference of interest for the study concerns the interaction term at week 12.
Assuming correlation coefficients equal to r_0_6_weeks = 0.71, r_0_12_weeks = 0.65 and r_6_12_weeks = 0.69 for the 0-6, 0-12 and 6-12 week intercorrelations, respectively, in the primary outcome values (PHQ-9), with a standard deviation of 5.60 at week 12 (numbers drawn from the results of the NCT06361667 trial) and a Cohen's d for the interaction term that is equal to 0.258 at week 12 for PHQ-9, at a type I error set at 5%, 205 participants per intervention arm would be needed for the achievement of 80% statistical power; importantly, assuming an anticipated 20% loss at follow-up rate, the total number required is 410/0.8, yielding 512 participants (256 participants by treatment arm). The power calculation was performed using the GLIMMPSE online statistical software (https://glimmpse.samplesizeshop.org/)
Sensitivity analyses will be carried out, including site as a fixed/random effects factor in the models. In case of missing longitudinal data, sensitivity analyses will be performed using maximum likelihood / Last Observation Carried Forward (LOCF) approaches.
7,201 studies on the registry are indexed under Anxiety Disorders; 1,682 are open to participants now.
This study's enrollment of 541 is above the median of 80 across 6,057 interventional studies indexed under Anxiety Disorders.
Browse Anxiety Disorders studies →KAVADIA ELENI is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The study will be advertised to public and private mental health professionals across Greece, including those in public hospitals, day care centres, and non-governmental and non-profit organisations. Clinicians will then refer potential participants to the study.
Inclusion Criteria:
Exclusion Criteria:
This arm will receive the arts intervention (any of the arts interventions)
Other: Art Prescription
This arm will remain in the waiting list during the 12-week period
Any of the art interventions (theatre, dance, visual arts, music or cinema)
The Patient Health Questionnaire-9 (PHQ-9)
The Patient Health Questionnaire-9 (PHQ-9) is a questionnaire which measures depression and grade severity of symptoms in general medical and mental health settings using nine DSM-5 criteria for major depression within the last two weeks. PHQ-9 was constructed in 2001 and has been validated in Greek in 2011, using a four-point Likert-type scale. After summing all responses (0=not at all, 3=nearly every day), scores range from 0 to 27, with higher levels indicating increased symptom severity (0-4 no to minimal; 5-9 mild; 10-14 moderate; 15-19 moderately severe; 20-27 severe). The reliability of the PHQ-9 was excellent, with a Cronbach's alpha of 0.89 in the PHQ Primary Care Study and 0.82 in the Greek validation study.
Time frame: From enrollment to the end of intervention at 12 weeks
Generalised Anxiety Disorder Assessment (GAD-7)
The Generalised Anxiety Disorder Assessment (GAD-7) is provided to screen symptom severity for the four most common anxiety disorders (generalized anxiety disorder, panic disorder, social phobia and posttraumatic stress disorder). GAD-7 was constructed in 2006 and was validated in Greek in 2022. It consists of 7 items. The GAD-7 score is computed by assigning scores of 0, 1, 2, and 3, to the response categories of 'not at all', 'several days', 'more than half the days', and 'nearly every day', respectively, and summing together the scores for the seven questions (scores range from 0 to 21). Higher levels indicate increased anxiety. There are cut-offs for severity of anxiety as: (i) score 0-4: Minimal Anxiety; (ii) score 5-9: Mild Anxiety; (iii) score 10-14: Moderate Anxiety; (iv) score greater than 15: Severe Anxiety. The internal consistency of the GAD-7 has been excellent.
Time frame: From enrollment to the end of intervention at 12 weeks
The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS). This tool was developed in 2007, in order to measure mental wellbeing in the general population. It consists of 14 items responding using a 5-point Likert scale from 1 (never) to 5 (all the time). The overall score is calculated by summing the responses for every item without reversing none. The minimum overall score ranges from 14 to 70. Higher scores indicate increased mental wellbeing. The scale has been widely used nationally and internationally for monitoring, evaluating projects and programmes and investigating the determinants of mental wellbeing. An efficient internal consistency was proven using Cronbach's alpha score which was 0.89 for the student sample and 0.91 for the general population sample. Also, test-retest reliability at one week was high (0.83). The Greek validation study showed acceptable internal consistency (Cronbach's alpha score 0.90).
Time frame: From enrollment to the end of intervention at 12 weeks
UCLA 3-item Loneliness Scale
The Revised UCLA Loneliness Scale-20 (UCLA-20) is a questionnaire which measures level of psychological loneliness experienced by a person. UCLA-20 was constructed in 1980 and was validated in Greek in 1992. The internal reliability of the UCLA-20 was excellent, with a Cronbach's alpha of 0.94 in the original study and and 0.89 in the Greek validation study. In 2004, this long scale was shortened to 3 questions (UCLA 3-item Loneliness Scale) in order to be used in large surveys. It is using a 3-point Likert-type scale (hard ever, some of the time, often). The scores can be added together to give a range of scores from 3 to 9. Higher scores mean most lonely (worse outcome).
Time frame: From enrollment to the end of intervention at 12 weeks
Plan to share: No
Ran from Sep 2025 to primary completion in Feb 2026, 5 months.
Of 3,836 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 5 months is below that.
Counting every sponsor, half of 3,938 studies reached it within 12 months; a quarter within 5 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
KAVADIA ELENI